The global spread of COVID-19 has imparted significant economic, medical, and social burdens. Like adults, children are affected by this pandemic. However, milder clinical symptoms are often experienced by them. Only a minimal proportion of the affected patients may develop severe and complicated COVID-19. Supportive treatment is recommended in all patients. Antiviral and immunomodulatory medications are spared for hospitalized children with respiratory distress or severe to critical disease. Up till now, remdesivir is the only USFDA-approved anti-COVID-19 medication indicated in the majority of symptomatic patients with moderate to severe disease. Dexamethasone is solely recommended in patients with respiratory distress maintained on oxygen or ventilatory support. The use of these medications in pediatric patients is founded on evidence deriving from adult studies. No randomized controlled trials (RCTs) involving pediatric COVID-19 patients have assessed these medications’ efficacy and safety, among others. Similarly, three novel monoclonal anti-SARS-CoV-2 spike protein antibodies, bamlanivimab, casirivimab and imdevimab, have been recently authorized by the USFDA. Nonetheless, their efficacy has not been demonstrated by multiple RCTs. In this review, we aim to dissect the various potential therapeutics used in children with COVID-19. We aspire to provide a comprehensive review of the available evidence and display the mechanisms of action and the pharmacokinetic properties of the studied therapeutics. Our review offers an efficient and practical guide for treating children with COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, Therapeutics, Pediatric patients, 【초록키워드】 Dexamethasone, Randomized controlled trial, Treatment, antibodies, Efficacy, pandemic, Hospitalized, pediatric, children, Remdesivir, oxygen, anti-SARS-CoV-2, bamlanivimab, Spike protein, Adults, Symptomatic patients, Casirivimab, Imdevimab, Pediatric patients, Patient, Efficacy and safety, medication, moderate, patients, mechanism, monoclonal, Critical disease, RCTs, pharmacokinetic, Evidence, distress, severe disease, COVID-19 patient, respiratory distress, moderate to severe, ventilatory support, Pediatric patient, Supportive treatment, among others, clinical symptom, offer, spread of COVID-19, affected, develop, proportion, indicated, majority, demonstrated, Like, dissect, children with COVID-19, immunomodulatory medication, symptomatic patient, 【제목키워드】 Pediatric patient,